Design, synthesis and in-vitro anti-depressant activity evaluation of some 2-styrylbenzimidazole derivatives

Future Journal of Pharmaceutical Sciences

Table 2 Molecular properties of designed ligands

Compound code	miLogP	TPSA	nAtoms	MW	nHBA	nHBD	nNiolations	nRB
MS1	4.33	43.85	24	311.39	3	2	0	3
MS2	4.89	51.97	26	360.44	4	0	0	4
MS3	2.99	83.55	25	330.35	6	2	0	3
MS4	4.85	43.85	25	329.38	3	2	0	3
MS5	3.03	55.21	24	317.35	5	0	0	3
MS6	4.92	17.83	24	310.4	2	0	0	3
MS7	4.65	17.83	24	330.82	2	0	0	3
MS8	4.39	17.83	24	375.27	2	0	0	3
MS9	5.7	21.06	25	331.46	3	0	1	5
MS10	3.86	30.30	25	333.44	4	0	0	5
MS11	4.44	43.85	25	325.42	3	2	0	4
MS12	5.93	43.85	25	325.42	3	2	1	4
MS13	6.12	17.83	24	330.82	2	0	1	3
MS14	5.34	51.97	27	374.46	4	0	1	4
MS15	6.06	30.72	23	297.36	3	0	1	3
MS16	4.22	56.74	24	312.38	4	2	0	3
MS17	6.25	17.83	25	344.85	2	0	1	4
MS18	6.23	17.83	25	344.85	2	0	1	4
MS19	3.83	30.30	23	305.38	4	0	0	4
MS20	5.36	21.06	26	339.44	3	0	1	4
MS21	5.31	27.06	25	326.40	3	0	1	4
MS22	6.04	17.83	26	358.87	2	0	1	5
MS23	5.95	17.83	26	342.42	2	0	1	5
MS24	6.44	17.83	26	358.87	2	0	1	5
MS25	7.07	17.83	27	393.32	2	0	1	5
MS26	6.04	17.83	27	360.41	2	0	1	5
MS27	4.78	30.72	23	297.36	3	0	0	3
MS28	6.63	17.83	27	346.43	2	0	1	3
MS29	5.25	17.83	23	296.37	2	0	1	3
MS30	4.72	33.62	22	285.35	3	1	0	3
MS31	5.46	17.83	22	302.40	2	0	1	3
MS32	5.87	17.83	24	310.40	2	0	1	3
MS33	4.78	38.05	24	312.37	3	1	0	3
MS34	5.20	38.05	24	312.37	3	1	1	3
MS35	5.31	27.06	25	326.40	3	0	1	4
MS36	4.89	21.06	23	303.41	3	0	0	3
MS37	5.13	21.06	24	317.44	3	0	1	3
MS38	3.88	24.30	24	318.42	4	0	0	3
MS39	6.25	17.83	25	344.85	2	0	1	4
MS40	5.21	63.65	26	341.37	5	0	1	4